Invivyd completes enrollment in phase 3 COVID antibody trial

June 1, 2026 7:02 AM

Invivyd Inc. (NASDAQ: IVVD) announced completion of enrollment in its DECLARATION clinical trial, a phase 3 study evaluating VYD2311, an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found